Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-124758
Filing Date
2024-11-12
Accepted
2024-11-12 09:43:35
Documents
92
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q axsm-20240930.htm   iXBRL 10-Q 2550404
2 EX-10.1 axsm-ex10_1.htm EX-10.1 95225
3 EX-10.2 axsm-ex10_2.htm EX-10.2 58164
4 EX-10.3 axsm-ex10_3.htm EX-10.3 76205
5 EX-10.4 axsm-ex10_4.htm EX-10.4 77417
6 EX-31.1 axsm-ex31_1.htm EX-31.1 15003
7 EX-31.2 axsm-ex31_2.htm EX-31.2 14905
8 EX-32.1 axsm-ex32_1.htm EX-32.1 6998
9 EX-32.2 axsm-ex32_2.htm EX-32.2 6976
  Complete submission text file 0000950170-24-124758.txt   10815800

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT axsm-20240930.xsd EX-101.SCH 1527568
95 EXTRACTED XBRL INSTANCE DOCUMENT axsm-20240930_htm.xml XML 1766176
Mailing Address ONE WORLD TRADE CENTER, 22ND FLOOR NEW YORK NY 10007
Business Address ONE WORLD TRADE CENTER, 22ND FLOOR NEW YORK NY 10007 (212) 332-3241
Axsome Therapeutics, Inc. (Filer) CIK: 0001579428 (see all company filings)

EIN.: 454241907 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37635 | Film No.: 241444347
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)